What is it used for?
DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy . …DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy . …
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- datopotamab deruxtecandatopotamab deruxtecan
- Form and strength
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 100 mg / 5 mLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 100 mg / 5 mL
- Manufacturer / applicant
- DAIICHI SANKYO INC.DAIICHI SANKYO INC.
For injection: 100 mg of datopotamab deruxtecan-dlnk as a white to yellowish white, lyophilized powder in a single-dose vial for reconstitution and further dilution.For injection: 100 mg of datopotamab deruxtecan-dlnk as a white to yellowish white, lyophilized powder in a single-dose vial for reconstitution and further dilution.
Safety and clinical review
- Interstitial Lung Disease/PneumonitisInterstitial Lung Disease/Pneumonitis
- Ocular Adverse ReactionsOcular Adverse Reactions
- StomatitisStomatitis
- Embryo-Fetal ToxicityEmbryo-Fetal Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Datroway used for?
DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy . …DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy . …
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Datroway should I ask about?
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 100 mg / 5 mLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 100 mg / 5 mL
Read the primary sourceWhat determines the price of Datroway?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Datroway?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.